Clinical Trials Browser

Interventional × Melanoma × Bortezomib × Clear all

NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Phase 1 Completed

DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT01078961 2016-06-08

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Phase 1 Completed

Melanoma

NCT01462773 2015-01-13

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Phase 1 Completed

16 enrolled 5 charts

Melanoma

NCT00288041 2013-03-05

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Uveal Melanoma, Melanoma

NCT00024011 2013-01-16

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Phase 2 Completed

Melanoma

NCT00512798 2012-10-02

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Phase 1/2 Terminated

47 enrolled 9 charts

CNSDermatologic

Brain Neoplasms, Melanoma, Central Nervous System Neoplasms

NCT00667641 2011-05-10

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Phase 1 Completed

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms